ClinicalTrials.gg
RecruitingNCT05781516Updated Mar 27, 2023

Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RD

An interventional study of Prednisolone and Baricitinib in IgG4-related Disease With Eosinophilia, sponsored by Wen Zhang. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-03-27.

Sponsored by Wen Zhang · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Immunoglobulin G4-Related Disease with a site in China — 24 open to participants now, 28 under way, 5 of them phase 3. Immunoglobulin G4-Related Disease · China.

Planned enrollment
11th of 37
74 · median 58
Started
2023
with 5 others
No phase
11 of 41
7 open now
Primary completion
2024-06
later than 1 of 27 live
Registered
16th of 41
by date
Lead sponsor
3 of 41
Wen Zhang

Among the 41 studies in Immunoglobulin G4-Related Disease with a site in China, this one is the 11th largest by planned enrollment of the 37 interventional ones that give a count, is one of 6 that started in 2023, is one of 11 with no phase, reaches primary completion later than 1 of the 27 other live ones, and was the 16th registered.

Immunoglobulin G4-Related Disease

73 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.

Browse Immunoglobulin G4-Related Disease studies →

Open to participants now

24 of the 41 studies in Immunoglobulin G4-Related Disease with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 27 Immunoglobulin G4-Related Disease studies recruiting now, 11 (41%) set no upper age limit and 13 (48%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Immunoglobulin G4-Related Disease with a site in China, or all of them as a file.
02

Study summary

Evaluation of efficacy and safety of Baricitinib combined with glucocorticoid in patients of IgG4-related disease with eosinophilia.

Read the detailed description

This is a multicenter, 52-week prospective, randomized controlled study to compare the efficacy and safety of Baricitinib combined with glucocorticoid and glucocorticoid monotherapy in proliferative IgG4-RD patients with eosinophilia.

03

Conditions studied

  • IgG4-related Disease With Eosinophilia

Keywords

  • IgG4-related disease
  • eosinophilia
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All patients must meet the following diagnostic criteria of IgG4RD (2020): 1) and radiological features: One or more organs show diffuse or localized swelling or a mass or nodule characteristic of IgG4-RD. In single organ involvement, lymph node swelling is omitted. 2) serological diagnosis: Serum IgG4 levels greater than 135 mg/dl. 3) diagnosis diagnosis: Positivity for two of the following three criteria: a. Dense lymphocyte and plasma cell infiltration with fibrosis. b. Ratio of IgG4-positive plasma cells /IgG-positive cells greater than 40% and the number of IgG4-positive plasma cells greater than 10 per high powered field. c. Typical tissue fibrosis, particularly storiform fibrosis, or obliterative phlebitis.

    Patients fulfill (1) + (2) + (3) are diagnosed as definite IgD4RD; (1) + (2): possible IgG4RD; (1) + (3): probable IgG4RD. exclusion of other diseases.

  2. Active IgG4-RD (Responder Index ≥ 2 points for each involved organ)
  3. The counts of peripheral blood eosinophil cells ≥0.75×109/L

Exclusion criteria

Exclusion Criteria:

  1. Patients who is not able to discontinue GC
  2. Pregnancy or breastfeeding or planning to get pregnant within 2 years
  3. Received , , biological agents or JAK inhibitors within 3 months
  4. Allergic to Baricitinib
  5. Concomitant other diseases
  6. Chronic infection, latent tuberculosis, or active infection
  7. Server liver or renal dysfunction, or heart failure.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (estimated)

Study arms

  • Placebo comparator
    Prednisolone monotherapy

    Oral prednisolone 0.6-0.8mg/kg daily for 4 weeks, then tapered and withdrawal in 4 months.

    Drug: Prednisolone

  • Experimental
    Prednisolone plus Baricitinib

    Oral prednisolone 0.6-0.8mg/kg daily for 4 weeks, then tapered and withdrawal in 4 months. Oral Baricitinib 2mg daily for 12 months.

    Drug: Prednisolone · Drug: Baricitinib

Interventions

  • Oral prednisolone 0.6-0.8mg/kg daily for 4 weeks, then tapered and withdrawal in 4 months.

  • Oral Baricitinib 2mg daily for 12 months.

06

What researchers measure

Primary outcomes

  1. The difference of recurrent rate of IgG4-RD between the two groups

    Clinical recurrence definition: any item of IgG4-RD Responder Index ≥2 (without treatment), or ≥ 3 (with treatment) or new organ involvement; with or without elevated serum IgG4 levels.

    Time frame: 52 weeks

Secondary outcomes

  1. The time of recurrence

    Clinical recurrence definition: any item of IgG4-RD Responder Index ≥2 (without treatment), or ≥ 3 (with treatment) or new organ involvement; with or without elevated serum IgG4 levels.

    Time frame: 0-52 weeks

  2. The changes of IgG4-related disease Responder Index

    According to international multispecialty validation study of IgG4-related disease Responder Index (Version: 13, December, 2015), Responder Index ≥ 0, and higher scores mean a worse outcome.

    Time frame: 52 weeks

  3. The changes of blood Eosinophil cells

    Percentages (%) and counts (109) of peripheral eosinophil cells

    Time frame: 52 weeks

  4. The changes of serum IgG levels

    Level of serum IgG(g/L)

    Time frame: 52 weeks

  5. The changes of serum IgG4 levels

    Level of serum IgG4(mg/dL)

    Time frame: 52 weeks

  6. The changes of serum hsCRP level

    Level of serum high-sensitivity C-reactive protein level(mg/L)

    Time frame: 52 weeks

  7. The changes of ESR

    Serum erythrocyte sedimentation rate(mm/h)

    Time frame: 52 weeks

  8. The percentages of adverse events

    Adverse effect of drugs

    Time frame: 52 weeks

  9. The changes of PGA

    Changes of patient global assessment from baseline, score (0-10, higher is worse)

    Time frame: 52 weeks

  10. The results of High-throughput analysis

    The changes of results from baseline in High-throughput analysis, including GWAS, single cell sequencing of B cell receptor.

    Time frame: 52 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Jun 2024, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2023
First posted
Mar 23, 2023
StartActual
Jan 20, 2023
Primary completionEst.
Jun 2024
CompletionEst.
Jun 2025
Last update
Mar 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05781516
Lead sponsor
Wen Zhang
Responsible party
Wen Zhang (Professor, Peking Union Medical College Hospital) — Sponsor-investigator
First posted
Mar 23, 2023
Start date
Jan 20, 2023
Primary completion
Jun 2024 (estimated)
Completion
Jun 2025 (estimated)
Last update
Mar 27, 2023

Study contacts

Linyi Peng, MD
Contact
drpenglinyi@163.com
+8615810395901
Wen Zhang, MD
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion